Comparison of lormetazepam solution and capsules in healthy volunteers: Early exposure and drug pharmacokinetics

Clinical Drug Investigation

Volumn 22, Issue 12, 2002, Pages 859-866

  Guerra, P ^a   Soto, A ^a   Carcas, A J ^b   Sancho, A ^b   Cassinello, A ^b   Frías Iniesta, Jesus ^b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LORMETAZEPAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SOLUTION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0036917417     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222120-00006     Document Type: Article

References (18)

1. Gaudreault P, Guay J, Thivierge RL, et al. Benzodiazepine poisoning: Clinical and pharmacological considerations and treatment. Drug Saf 1991; 6: 247-65
2. Gudex C. Adverse effects of benzodiazepines. Soc Sci Med 1991; 33: 587-96
3. Greenblatt DJ, Miller LG, Shader RI. Neurochemical and pharmacokinetic correlates of the clinical action of benzodiazepine hypnotic drugs. Am J Med 1990; 88 Suppl 3A: 18S-24S
4. Wheatley D. Prescribing short-acting hypnosedatives: Current recommendations from a safety perspective. Drug Saf 1992; 7: 106-15
5. Greenblatt DJ, Divoll M, Abernethy DR, et al. Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1983; 8: 233-52
6. Adam K, Oswald L. Effects of lormetazepam and of flurazepam on sleep. Br J Clin Pharmacol 1984; 17: 531-8
7. Huempel M, Nieuweboer B, Milius W, et al. Kinetics and biotransformation of lormetazepam: II. Radioimmunologic determinations in plasma and urine of young and elderly subjects: First-pass effect. Clin Pharmacol Ther 1980; 28: 673-9
8. Pierce DM, Franklin RA, Harry TVA, et al. Pharmacodynamic correlates of modified absorption: Studies with lormetazepam. Br J Cin Pharmacol 1984; 18: 31-5
9. Shein-Chung C, Jen-Pei L. Current issues in bioequivalence trials. Drug Inf J 1995; 29: 795-804
10. Steinijans VW, Diletti E. Generalization of distribution: Free confidence intervals for bioavailability ratios. Eur J Clin Pharmacol 1985; 28 (1): 85-8
11. Zecca L, Reina L, Scaglione F, et al. Relative bioavailability in humans for oral tablets and solutions of lormetazepam. Arzneimittel Forschung 1985; 35 (12): 1870-2
12. Zecca L, Ferrario P, Fraschini F, et al. Determination of lormetazepam in plasma by gas chromatography and electron-capture detection. J Chromatogr 1986 Apr 25; 377: 368-72
13. Karch FE, Lasagna L. Towards the operational identification of adverse drug reaction. Clin Pharmacol Ther 1977; 21: 247-54
14. FDA. Guidance for Industry. BA and BE Studies for Orally Administered Drug Products: General Considerations: FDA-CEDER, Rockville, MD, USA, 1999 Aug
15. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990 Feb 28; 2: 72-8
16. Wijnand HP. On the assessment of bioequivalence in a two period cross-over design. Comput Methods Programs Biomed 1992; 37: 151-7
17. Hildebrand M, Hellstern A, Hümpel M, et al. Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers. Eur J Drug Metab Pharmacokinet 1990; 15 (1): 19-26
18. Luscombe DK. Lormetazepam: Plasma concentrations in volunteers following sublingual and oral dosing. Psychopharmacology Suppl 1984; 1: 99-104